ITIH6

Summary

ITIH6 (inter-alpha-trypsin inhibitor heavy chain family member 6, HGNC:28907) is a protein-coding gene on chromosome Xp11.22, encoding Inter-alpha-trypsin inhibitor heavy chain H6 (Q6UXX5).

The protein encoded by this gene belongs to the interalpha trypsin inhibitor heavy chain (ITIH) family. Interalpha trypsin inhibitor (ITI) is composed of two heavy chains (containing VWA domain) and one light chain. The light chain confers the protease-inhibitor function, while the heavy chains are involved in mediating protein-protein interactions with the components of the extracellular matrix.

Source: NCBI Gene 347365 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 260 total — 1 pathogenic
• MANE Select transcript: NM_198510

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28907
Approved symbol	ITIH6
Name	inter-alpha-trypsin inhibitor heavy chain family member 6
Location	Xp11.22
Locus type	gene with protein product
Status	Approved
Aliases	UNQ6369
Ensembl gene	ENSG00000102313
Ensembl biotype	protein_coding
Entrez	347365

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000218436, ENST00000498398

RefSeq mRNA: 1 — MANE Select: NM_198510 NM_198510

CCDS: CCDS14361

Canonical transcript exons

ENST00000218436 — 13 exons

Exon	Start	End
ENSE00000671694	54753651	54753764
ENSE00000671696	54759756	54759927
ENSE00000821381	54751003	54751380
ENSE00000821384	54791926	54792036
ENSE00001331370	54748918	54750106
ENSE00001335765	54790837	54791084
ENSE00001335777	54788480	54788649
ENSE00001335778	54796942	54797096
ENSE00001380437	54774081	54774197
ENSE00001383439	54753930	54753965
ENSE00001419541	54798109	54798255
ENSE00001435259	54755017	54755109
ENSE00001465699	54756965	54758998

Expression profiles

Bgee: expression breadth broad, 19 present calls, max score 74.81.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0471 / max 39.6316, expressed in 8 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199397	0.0471	8

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	74.81	gold quality
gastrocnemius	UBERON:0001388	70.32	gold quality
muscle of leg	UBERON:0001383	68.39	gold quality
hindlimb stylopod muscle	UBERON:0004252	64.70	gold quality
buccal mucosa cell	CL:0002336	62.81	gold quality
pancreatic ductal cell	CL:0002079	62.78	silver quality
epithelial cell of pancreas	CL:0000083	54.99	gold quality
tendon of biceps brachii	UBERON:0008188	54.89	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
skeletal muscle tissue	UBERON:0001134	54.33	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
heart right ventricle	UBERON:0002080	54.18	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	54.12	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
muscle tissue	UBERON:0002385	53.05	gold quality
nasal cavity epithelium	UBERON:0005384	52.16	gold quality
colonic epithelium	UBERON:0000397	50.25	gold quality
myocardium	UBERON:0002349	50.25	gold quality
tibialis anterior	UBERON:0001385	50.11	silver quality
deltoid	UBERON:0001476	49.52	gold quality
medial globus pallidus	UBERON:0002477	49.03	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	47.78	gold quality
quadriceps femoris	UBERON:0001377	47.29	gold quality
globus pallidus	UBERON:0001875	47.02	gold quality
ileal mucosa	UBERON:0000331	46.40	silver quality
nasal cavity mucosa	UBERON:0001826	46.29	gold quality
vastus lateralis	UBERON:0001379	46.07	gold quality
upper leg skin	UBERON:0004262	46.04	silver quality
skin of hip	UBERON:0001554	43.82	silver quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93
E-GEOD-81383	no	167.12

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting ITIH6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-2053	99.57	69.15	1635
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-6780B-3P	99.13	67.18	622
HSA-MIR-4711-3P	98.97	66.87	1020
HSA-MIR-873-5P	98.84	66.90	1348
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-4716-5P	98.82	68.57	1168
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-6529-3P	98.68	66.76	1020

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	itih6	ENSDARG00000056037
mus_musculus	Itih6	ENSMUSG00000087149
rattus_norvegicus	Itih6	ENSRNOG00000069211

Paralogs (11): ITIH4 (ENSG00000055955), ITIH1 (ENSG00000055957), PARP4 (ENSG00000102699), VWA5A (ENSG00000110002), ITIH5 (ENSG00000123243), VWA5B2 (ENSG00000145198), ITIH2 (ENSG00000151655), VWA5B1 (ENSG00000158816), ITIH3 (ENSG00000162267), VWA3B (ENSG00000168658), VWA3A (ENSG00000175267)

Protein

Protein identifiers

Inter-alpha-trypsin inhibitor heavy chain H6 — Q6UXX5 (reviewed: Q6UXX5)

Alternative names: Inter-alpha-trypsin inhibitor heavy chain H5-like protein

All UniProt accessions (1): Q6UXX5

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Secreted.

Similarity. Belongs to the ITIH family.

RefSeq proteins (1): NP_940912* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002035	VWF_A	Domain
IPR010600	ITI_HC_C	Domain
IPR013694	VIT	Domain
IPR036465	vWFA_dom_sf	Homologous_superfamily
IPR050934	ITIH	Family

Pfam: PF00092, PF06668, PF08487

UniProt features (22 total): glycosylation site 6, compositionally biased region 4, sequence variant 4, region of interest 4, domain 2, signal peptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UXX5-F1	65.33	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (6): 83, 374, 540, 594, 971, 1231

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 37 (showing top): GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_HYALURONAN_METABOLIC_PROCESS, GOBP_AMINOGLYCAN_METABOLIC_PROCESS, TGGNNNNNNKCCAR_UNKNOWN, DBP_Q6, HOXA4_Q2, GOMF_PEPTIDASE_REGULATOR_ACTIVITY, GOMF_SERINE_TYPE_ENDOPEPTIDASE_INHIBITOR_ACTIVITY, GOMF_ENZYME_INHIBITOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, chrXp11, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GOMF_ENDOPEPTIDASE_REGULATOR_ACTIVITY, MIR7_1_3P, MIR7_2_3P

GO Biological Process (1): hyaluronan metabolic process (GO:0030212)

GO Molecular Function (3): serine-type endopeptidase inhibitor activity (GO:0004867), protein binding (GO:0005515), peptidase inhibitor activity (GO:0030414)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycosaminoglycan metabolic process	1
serine-type endopeptidase activity	1
endopeptidase inhibitor activity	1
binding	1
enzyme inhibitor activity	1
peptidase activity	1
peptidase regulator activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

932 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ITIH6	OR6C65	A6NJZ3	667
ITIH6	GUCY2F	P51841	492
ITIH6	INTS6L	Q5JSJ4	478
ITIH6	AWAT1	Q58HT5	450
ITIH6	ZNF630	Q2M218	447
ITIH6	GLT8D1	Q68CQ7	438
ITIH6	SATL1	Q86VE3	434
ITIH6	MTRNR2L10	P0CJ77	418
ITIH6	VCF2	Q5XKR9	393
ITIH6	CFAP47	Q6ZTR5	386
ITIH6	PAGE2B	Q5JRK9	380
ITIH6	GPM6B	Q13491	376
ITIH6	RAB9A	P51151	375
ITIH6	ZNF142	P52746	373
ITIH6	OR6C6	A6NF89	368

IntAct

27 interactions, top by confidence:

A	B	Type	Score
KRTAP6-1	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
ANKS1A	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
SMIM29	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
ITIH6	ZNF414	psi-mi:“MI:0915”(physical association)	0.560
TLX3	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
VENTX	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
KPRP	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
EVX2	ITIH6	psi-mi:“MI:0915”(physical association)	0.560
Csk	CELF2	psi-mi:“MI:0914”(association)	0.350
ITIH6	CNPY4	psi-mi:“MI:0914”(association)	0.350
KRTAP6-1	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
ANKS1A	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
SMIM29	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
ZNF414	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
TLX3	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
VENTX	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
KPRP	ITIH6	psi-mi:“MI:0915”(physical association)	0.000
EVX2	ITIH6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): ITIH6 (Affinity Capture-MS), ITIH6 (Two-hybrid), ZNF414 (Two-hybrid), VENTX (Two-hybrid), TLX3 (Two-hybrid), EVX2 (Two-hybrid), KRTAP6-1 (Two-hybrid), C6orf1 (Two-hybrid), KPRP (Two-hybrid), KIAA1522 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), FKBP14 (Affinity Capture-MS), TIMM21 (Cross-Linking-MS (XL-MS)), ITIH6 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A2RU67, D3YX43, D3ZWJ9, D5K8A9, E9Q8Q8, O70540, P0CI71, P17813, P28906, P37176, P40967, P51693, P59383, Q03157, Q06154, Q08DV9, Q14956, Q17R55, Q3U3D7, Q3ULW6, Q5F3L3, Q5R6F5, Q5SZV5, Q60696, Q60943, Q61826, Q63961, Q64314, Q6P7C7, Q6UXX5, Q7TN88, Q7Z442, Q866Y3, Q8BYI8, Q8C0Z1, Q8CB67, Q8K4C2, Q8N3G9, Q8R526, Q8VHF2

Diamond homologs: A2VE29, A6X935, O02668, P19823, P19827, P56652, P79263, P97278, P97279, P97280, Q06033, Q0VCM5, Q14624, Q29052, Q3T052, Q5RB37, Q5RER0, Q61702, Q61703, Q61704, Q63416, Q6UXX5, Q86UX2, Q8BJD1, Q9GLY5, A8XP97, P34374, P56651, A1A5Q7, Q5RJF7, A6NCI4, Q8CFG5, Q8IZS8, Q9Z1L5, Q3UVV9, Q9ZQ46

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

260 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	207
Likely benign	20
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
599598	NM_198510.3(ITIH6):c.2377C>T (p.Gln793Ter)	Pathogenic

SpliceAI

2220 predictions. Top by Δscore:

Variant	Effect	Δscore
X:54753645:TCTTA:T	donor_loss	1.0000
X:54753646:CTTA:C	donor_loss	1.0000
X:54753647:TTA:T	donor_loss	1.0000
X:54753648:TAC:T	donor_loss	1.0000
X:54753650:C:A	donor_loss	1.0000
X:54753762:CCA:C	acceptor_gain	1.0000
X:54753763:CAC:C	acceptor_gain	1.0000
X:54753765:C:CC	acceptor_gain	1.0000
X:54755039:T:TA	donor_gain	1.0000
X:54759754:A:AC	donor_gain	1.0000
X:54759754:ACAG:A	donor_gain	1.0000
X:54759754:ACAGC:A	donor_gain	1.0000
X:54759755:C:CC	donor_gain	1.0000
X:54759755:CA:C	donor_gain	1.0000
X:54759755:CAGC:C	donor_gain	1.0000
X:54759755:CAGCC:C	donor_gain	1.0000
X:54759767:T:TA	donor_gain	1.0000
X:54759937:A:C	acceptor_gain	1.0000
X:54759941:A:C	acceptor_gain	1.0000
X:54791922:TTA:T	donor_loss	1.0000
X:54791923:TA:T	donor_loss	1.0000
X:54791924:A:AC	donor_gain	1.0000
X:54791924:A:AT	donor_loss	1.0000
X:54791925:C:CC	donor_gain	1.0000
X:54792032:TGGTC:T	acceptor_gain	1.0000
X:54792033:GGTC:G	acceptor_gain	1.0000
X:54792034:GTC:G	acceptor_gain	1.0000
X:54792035:TC:T	acceptor_gain	1.0000
X:54792035:TCCT:T	acceptor_loss	1.0000
X:54792036:CCTAA:C	acceptor_gain	1.0000

AlphaMissense

8453 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:54791021:A:C	F144L	0.992
X:54791021:A:T	F144L	0.992
X:54791023:A:G	F144L	0.992
X:54791022:A:G	F144S	0.989
X:54791063:G:C	F130L	0.984
X:54791063:G:T	F130L	0.984
X:54791065:A:G	F130L	0.984
X:54759859:A:C	F324L	0.981
X:54759859:A:T	F324L	0.981
X:54759861:A:G	F324L	0.981
X:54797035:A:T	V55D	0.981
X:54797030:A:G	S57P	0.980
X:54788523:A:T	V248D	0.978
X:54797016:A:C	N61K	0.978
X:54797016:A:T	N61K	0.978
X:54796986:A:C	F71L	0.977
X:54796986:A:T	F71L	0.977
X:54796988:A:G	F71L	0.977
X:54796994:C:G	A69P	0.977
X:54791064:A:G	F130S	0.976
X:54796987:A:G	F71S	0.975
X:54797081:A:C	Y40D	0.974
X:54796948:A:G	F84S	0.973
X:54788529:A:G	F246S	0.970
X:54791016:A:G	L146P	0.970
X:54751053:A:G	F1227S	0.968
X:54796981:A:G	L73P	0.967
X:54788564:C:A	Q234H	0.966
X:54788564:C:G	Q234H	0.966
X:54751207:A:G	W1176R	0.965

dbSNP variants (sampled 300 via entrez): RS1000070996 (X:54786902 G>A), RS1000084327 (X:54775531 A>G), RS1000237378 (X:54754943 C>T), RS1000287836 (X:54775942 A>T), RS1000444449 (X:54795998 G>A), RS1000490930 (X:54756371 C>T), RS1000711768 (X:54766010 C>G), RS1000835782 (X:54795712 C>G), RS1000911886 (X:54748944 T>C), RS1000941678 (X:54757333 G>A), RS1001167024 (X:54763624 T>A), RS1001181409 (X:54794162 G>A), RS1001394401 (X:54796372 A>G), RS1001530465 (X:54752146 A>G), RS1001594446 (X:54752487 G>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002789_2	Egg allergy	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007018	egg allergy measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	affects cotreatment, decreases expression	2
bisphenol A	increases methylation	1
ferrous chloride	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Copper	decreases expression, affects cotreatment	1
Plant Extracts	decreases expression, affects cotreatment	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice